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Pneumocystis jirovecii is a symbiotic respiratory fungus that causes pneumonia (PcP) in immunosuppressed patients. Because P.
jirovecii cannot be reliably cultured in vitro, it has proven difficult to study and gaps in our understanding of the organism per-
sist. The release of a draft genome for the organism opens the door for the development of new genotyping approaches for study-
ing its molecular epidemiology and global population structure. We identified and validated 8 putatively neutral microsatellite
markers and 1 microsatellite marker linked to the dihydropteroate synthase gene (dhps), the enzymatic target of sulfa drugs used
for PcP prevention and treatment. Using these tools, we analyzed P. jirovecii isolates from HIV-infected patients from three geo-
graphically distant populations: Uganda, the United States, and Spain. Among the 8 neutral markers, we observed high levels of
allelic heterozygosity (average He, 0.586 to 0.842). Consistent with past reports, we observed limited global population structur-
ing, with only the Ugandan isolates showing minor differentiation from the other two populations. In Ugandan isolates that har-
bored mutations in dhps, the microsatellite locus linked to dhps demonstrated a depressed He, consistent with positive direc-
tional selection for sulfa resistance mutations. Using a subset of these microsatellites, analyses of individual and paired samples
from infections in San Francisco, CA, showed reliable typeability within a single infection and high discriminatory power be-
tween infections. These features suggest that this novel microsatellite typing approach will be an effective tool for molecular-
epidemiological investigations into P. jirovecii population structure, transmission, and drug resistance.
Pneumocystis jirovecii is a symbiotic respiratory fungus thatcauses pneumonia (PcP) in immunocompromised patients,
including those with AIDS. In the United States, the incidence of
PcP in HIV-infected populations has significantly declined owing
to PcP prophylaxis and initiation of combined antiretroviral ther-
apy (cART) for HIV infection (1–3). However, PcP remains a
leading cause of death among those who do not receive cART or
PcP prophylaxis (4, 5). Among patients with HIV infection, mor-
tality rates for PcP remain high even in the cART era, ranging from
10% to nearly 40% (6–8). Concerningly, trends have suggested
that PcP is an increasingly important disease among HIV-infected
patients in low-income countries, where the majority of persons
with HIV infection reside (9). Despite advances in preventing PcP,
Pneumocystis is still cause for ample concern because (i) prophy-
laxis and treatment with sulfa drugs may be selecting for resistance
mutations in key P. jirovecii metabolic enzymes, including dihy-
drofolate reductase (encoded by dhfr) and dihydropteroate syn-
thase (encoded by dhps) (10–12); (ii) PcP incidence is increasing
in some parts of the world (13); and (iii) PcP outbreaks periodi-
cally occur in immunocompromised patient populations, causing
significant morbidity and mortality (13–20).
Because Pneumocystis cannot be reliably cultured in vitro (21),
fundamental questions about P. jirovecii biology, ecology, and ep-
idemiology remain unanswered. For example, we do not possess a
clear understanding of the Pneumocystis life cycle, including sex-
ual and clonal reproduction, transmission dynamics, the propensity
for Pneumocystis strains to persist in unaffected, immunocompe-
tent carriers, or the true risk of putatively sulfa drug-resistant
Pneumocystis strains (reviewed in reference 22). Molecular epide-
miology studies involving strain typing can help elucidate many of
these issues and, in particular, population structure, the evolution
of drug resistance, and transmission dynamics.
The current P. jirovecii strain-typing options have revealed
much about Pneumocystis population structure and outbreak dy-
namics (23, 24). These typing methods include single- and multi-
locus genotyping using karyotypes (25), multilocus enzyme elec-
trophoresis (25), Sanger sequence analysis (25, 26), type-specific
oligonucleotide hybridization (25), single-strand conformation
polymorphism (25), and multiplex-PCR/single-base extension
(MPCR/SBE) (27, 28). More recently, a four-locus scheme has
emerged, which includes internal transcribed spacer 1 (ITS1), 26S,
mt26S, and beta-tubulin (-TUB) (29, 30). Though each of these
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approaches has contributed significantly to our understanding of
Pneumocystis biology, many questions remain unresolved (27,
31). A genotyping approach with neutrally evolving markers, a
high discriminatory index, and a stepwise model of allele adapta-
tion would be a useful addition for studying P. jirovecii.
The publication of the draft P. jirovecii genome (32) enables the
development of such an approach. Using this information, we
have identified and validated assays for 8 putatively neutral mic-
rosatellites in order to develop a more robust multilocus strain
typing tool. Additionally, we have identified 1 microsatellite
linked to dhps, a gene in which mutations are thought to confer
reduced drug susceptibility to sulfa medications. Microsatellites
are short tandem repeats in coding and noncoding regions of the
genome that vary in length between strains and offer reproducible
genotype calling for individual strains (typeability) and high res-
olution to distinguish between strains (discriminatory power)
(33). This type of marker has been used extensively and has proven
to be robust in humans and in pathogens such as Plasmodium
falciparum for “molecular fingerprinting” and for studying the
evolution of drug resistance (34–36). Here, we describe our mul-
tilocus microsatellite genotyping method and use it to investigate
the global population structure of P. jirovecii, to study the evolu-
tion of sulfa antibiotic resistance, and to evaluate typeability and
discriminatory power within one cohort.
MATERIALS AND METHODS
Sample collection and ethics statement. Molecular analyses were per-
formed on deidentified clinical specimens from Uganda (2008 to 2009,
from Mulago Hospital, Makerere University), the United States (2005 to
2011, from San Francisco General Hospital, University of California, San
Francisco), and Spain (Barcelona, 2001 to 2004). Patients from Uganda
and San Francisco were enrolled on the basis of HIV infection and sus-
pected PcP, as described before (12). Patients from Spain were enrolled on
the basis of slide-positive microscopy, as described before (37). Among
the samples from Spain, 47% of cases were late presenters and 94% of
cases had not received previous sulfa or sulfone prophylaxis. Sample col-
lection and molecular analysis of isolates from each site were approved by
the appropriate Institutional Review Boards (IRBs) as described previ-
ously (12, 37, 38). As part of these prior studies, all specimens had been
genotyped for dihydropteroate synthase gene (dhps) mutations (12, 37,
39). Molecular analyses detailed in this study were approved by the Uni-
versity of North Carolina at Chapel Hill IRB (study no. 12-1783).
Identifying and validating microsatellites. In order to identify mic-
rosatellites, we scanned the published P. jirovecii genome (32) using Tan-
dem Repeat Finder (40), which identified approximately 150 di- or trinu-
cleotide tandem repeats with a repeat size of 8. For these, we were able to
design primers to amplify 50 tandem repeats using WebSat (41, 42). PCRs
were optimized on five total isolates from Kampala, Uganda, San Fran-
cisco, CA, and Chapel Hill, NC, and amplicons were sequenced using ABI
BigDye Terminator Chemistry (Applied Biosystems, Grand Island, NY).
Chromatograms were analyzed in Sequencher v5.0 (Gene Codes Corp.,
Ann Arbor, MI) to determine repeat unit counts, and sequence data were
deposited in GenBank (see below). Loci that showed evidence of 1 re-
peat-unit variation in pairwise comparisons among sequenced isolates
were deemed true microsatellites.
We assessed the functional genic context (i.e., intergenic, intragenic,
exonic, and intronic) of each true microsatellite using the annotations at
the European Nucleotide Archive (accession no. PRJEA68827), which
were created using Maker v2.10 (32, 43). This annotation pipeline utilized
de novo, homology, protein, and transcriptomic evidence (from 5  107
RNA-Seq reads) to predict the genic features. Physical linkage with the
dhps locus was determined using BLAST alignment (44) of published
P. jirovecii genome contigs against P. murina supercontigs (Liang Ma,
personal communication, December, 2012; genome downloaded from
the Broad Institute [http://www.broadinstitute.org/annotation/genome
/Pneumocystis_group.2/MultiHome.html]).
Amplification and fragment sizing. Fluorescently tagged forward
primers for each variable microsatellite locus were designed (Applied Bio-
systems, Foster City, CA). Reverse primers carried a 5= CTGTCTT “pig-
tail” to promote full adenylation and reduce stutter peaks (Table 1) (45).
PCR was performed using HotStarTaq (Qiagen, Valencia, CA) according
to the following generalized cycling parameters: 95°C for 15 min; 40 cycles
of 95°C for 45 s, primer-specific annealing temperature (Ta) for 45 s, 72°C
extension temperature for 60 s; 72°C extension temperature for 10 min;
12°C hold. To increase throughput, thermocycling was performed on Bio-
Rad T100 (Bio-Rad, Hercules, CA) or ABI 2720 (Applied Biosystems,
Foster City, CA) machines. For primer-specific sequences and Ta, see
Table 1.
PCR fragment length was determined on an ABI 310 genetic analyzer
and analyzed using ABI GeneMapper v4.1 software. A genomic DNA
(gDNA) standard from a P. jirovecii-positive clinical specimen isolated at
the University of North Carolina was used as an interrun standard to
adjust for batch variability in fragment sizes. Capillary electrophoresis was
performed using a denaturing polymer (POP-4; Applied Biosystems) in a
40-mm capillary at 60°C.
Excepting the possibility of diploidy, multiple microsatellite peaks
likely indicate a multiclone infection (22). In the case of multiple peaks,
the 2nd, 3rd, and 4th highest peaks were recorded if they were greater than
one-third of the maximum peak height and also greater than 100 fluores-
cence units. For analyses, haplotypes were built from dominant peaks at
each marker. This method of haplotype construction is reasonable, as
peak height is relatively quantitative, and this has become a standard ap-
proach in other organisms in which polyclonal infections are common
(46, 47). However, there is the potential that this method does not neces-





PjMS1 AAGATGACAACGAGAATTGGCT CTGTCTTAAAAGGCGATAAATGTGTGTCC 53.3
PjMS2 TCATATACCGATCCTTTGGGAG CTGTCTTGCCTGGACAATCCTGTCTCTAT 53.3
PjMS3 AATAGGCGGAATCTCACTAGCA CTGTCTTGACGGCAAAGAGTTGTTTCCT 53.3
PjMS4 ATCGTAGAAGGATGGAAAGAAG CTGTCTTGCAAATCGCATGTTCAAT 50.5
PjMS5 ACTGTACCTAATCTTTCATCGG CTGTCTTAAGGTTTTGGACGTTTGA 50.5
PjMS6 TGCTCGAATTGCAGTAGAGATT CTGTCTTCATCAGCAAGACGCTTAACTTG 55.2
PjMS7 GATCTGGGTTGAATATAAGCGT CTGTCTTTCTTTGGTTTCACAACAGCA 55.2
PjMS8 CTTTGATTGCTCACGATATGGA CTGTCTTATACGTTCACGGGCATAAGAGT 53.3
PjMS9 GAACTTTGTCTTTAACAGGACG CTGTCTTCTCAGTAGTAGCACCAATTCTTT 47.0
a Reverse primers have the 5= addition of a CTGTCTT “pigtail” to decrease stutter.
b Ta, temperature of primer annealing.
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sarily produce the single correct haplotype due to biases such as overam-
plification of shorter fragments during PCR. A further limitation to our
method, which is common to all multilocus genotyping schemes, is the
difficulty of assigning the correct phase of typed alleles in mixed popula-
tions. Fragment sizes were binned to the nearest repeat multiple. For most
analyses, data points 3 standard deviations beyond the overall mean re-
peat size for that marker were considered missing data, and any individual
with four or more missing data points was excluded from analysis.
Data analysis. Summary statistics and genetic linkage were deter-
mined per the following methods. Heterozygosity (He) was determined
using GenAlEx v6.5 for Microsoft Excel (48). He, a commonly used mea-
sure to quantify the diversity at a genetic locus in haploid organisms, is
defined as 1  i1
k Pi
2, where pi is the frequency of the ith of k alleles.
Linkage between genetic loci was determined in Arlequin v3.11 using an
exact test of linkage disequilibrium (49), in which haplotypic data were
arranged into contingency tables, and 105 Markov chains were used to
explore simulated data with 104 burn-in (dememorization) steps. Bonfer-
roni corrections were used to adjust significance levels for multiple com-
parisons.
Geographic population structure was determined per the following
methods. Distance matrices and phylogenetic trees were generated in
Populations v1.2.31 (http://bioinformatics.org/populations/) using the
Cavalli-Sforza and Edwards chord distance (51). RST (52) and FST (53)
measures of genetic differentiation between populations were calculated
in SPAGeDi v1.4 (54) as follows: RST  1  (SW/S), where S is twice the
estimated total allele size variance and SW is twice the estimated allele size
variance within subpopulations; and FST  1  (HS/HT), where HT is
total heterozygosity and HS is the mean heterozygosity within subpopu-
lations. Ninety-five percent confidence intervals were generated in SPA-
GeDi using jackknifing over loci with 1,000 permutations.
To further investigate population structure, we used a combination of
statistical and visual approaches. Fast UniFrac, a program for microbial
population genetic analysis, was used to measure the reproducibility of
the estimates of genetic distance between geographic populations (55).
The reproducibility of genetic splits between populations was assessed
using Monte Carlo simulations and jackknifing with 1,000 replicates.
Principal coordinates analysis (PCoA), a multidimensional scaling anal-
ysis, was carried out in the Fast UniFrac browser window. PCoA identifies
the main axes through a matrix using an eigenanalysis to quantitate dis-
similarity between populations. A median-joining network was calculated
and visualized in Network v4.611 (Fluxus Engineering, Suffolk, England).
These networks allow for a visual representation of the mutational paths
that may have led to the observed data and assume that mutations are
more likely to derive from a more frequent haplotype and proceed to a less
frequent haplotype.
In order to determine an optimal set of microsatellite loci for use in
transmission studies, we used Simpson’s index of diversity (D) to seek the
minimum number of microsatellite loci necessary to fully explain the
diversity of our data set (56). A Perl script was used to calculate Simpson’s
D for combinations of the microsatellite markers, using the following




Snjnj  1, where N is the total number of
parasite multilocus genotypes, s is the number of unique multilocus ge-
notypes, and nj is the count frequency of the jth multilocus genotype
variant (56). We added microsatellites to our scheme until D was 0.999
for our data set.
A set of six microsatellites was then used to investigate the relatedness
between clinical isolates and transmission using two approaches. A neigh-
bor-joining phylogeny (57) was generated in Populations v1.2.31, as out-
lined above, and visualized in the APE package for R (58). All samples
from San Francisco with genotype calls for at least one-half of the markers
(n  40) were used in this analysis. In addition, hypotheses of evolution-
ary descent and transmission were generated in eBURST v3 (59). In this
analysis, only samples with complete haplotypes for the selected markers
were used due to the design of the program (n  28). These analyses were
performed in the San Francisco cohort alone, as this was the only sample
set that contained paired samples from the same individuals.
Nucleotide sequence accession numbers. Data for the sequences de-
termined in this study were deposited in GenBank under accession num-
bers KF499042 to KF499075).
RESULTS
Of the 50 putative microsatellites identified and tested for inter-
strain length variability in the P. jirovecii genome, 9 were variable
and thus carried forward into analyses (Table 1). Based upon pre-
dicted genome annotations, one microsatellite locus was inter-
genic, seven loci were intragenic noncoding, and one was intra-
genic coding (see Table S1 in the supplemental material). P.
jirovecii isolates from 91 clinical specimens from Uganda, San
Francisco, and Spain were typed at all 9 loci, and complete haplo-
types were obtained for 63 (70%) isolates (Table 2). Amplification
efficacy for each marker ranged from 78.0% for MS8 to 97.8% for
MS1 (see Table S1 in the supplemental material). Each of the 9
markers was polyclonal in at least one sample. Similar to what was
observed in other studies (60, 61), a high proportion of the clinical
specimens were multiclonal: of the 91 BAL specimens, 63 (70%)
contained a minimum of two P. jirovecii strains (at least 1 micro-
satellite with two peaks) and 14 isolates (15%) contained a mini-
mum of three P. jirovecii strains (at least 1 microsatellite with three
peaks).
We assessed the variability of microsatellite repeats in order to
quantify which loci were most informative. To do this, we com-
puted summary statistics including heterozygosity (He) for each
marker, both overall and on a per-population basis (Fig. 1; see
Table S1 in the supplemental material). MS1 through MS8 had
high mean He values (0.5), indicating that they are diverse and
likely informative. In contrast, MS9 had a reduced He value
(0.5). Interestingly, MS9 showed highly depressed He values rel-
ative to MS1 to 8 in Uganda but had similar He values relative to
MS1 to 8 in Spain. Notably, all 13 Uganda samples contained
mutations in dhps (3 Thr55Ala/Pro57Ser double mutants and 10
Pro57Ser single mutants), but very few of the Spain samples (3/29)
contained mutations at dhps. Upon performing a scaffolded re-
construction of the P. jirovecii dhps region using Pneumocystis
murina supercontigs, we found that MS9 was located ca. 50 kb
upstream of the dhps locus. In pairwise tests of linkage disequilib-
rium, dhps was in significant linkage disequilibrium with MS9
(exact test, P  0.05); no other markers were near the dhps locus.
The fact that the dhps locus and MS9 are in linkage disequilib-
rium with one another enables studies to investigate the genetic
background of dhps mutations and to acquire evidence for a se-
lective sweep of dhps mutant alleles. Eleven dhps mutant samples
from Uganda and 14 dhps mutant samples from San Francisco









% of isolates with
dhps mutant
Uganda 13 10 0 100 (13/13)
San Francisco 49 28 5 65.3 (32/49)
Spain 29 25 0 10.3 (3/29)
All sources 91 63 5 52.7 (48/91)
a Complete haplotypes are isolates for which fragment length was determined for all
nine microsatellite markers.
b Paired samples represent two bronchoalveolar lavage samples taken from a single
patient, during either the same or different PcP episodes.
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with unambiguous MS9 genotype calls were used to construct
dhps-MS9 haplotypes (see Table S2 in the supplemental material).
In Uganda samples, we observed two unique dhps mutant geno-
types (Thr-Arg-Ser and Ala-Arg-Ser) and two MS9 alleles, (TA)9
and (TA)10. Of the four possible combinations of dhps and MS9
alleles, we identified three with an excess of Thr-Arg-Ser/(TA)10
haplotypes. In San Francisco samples, we observed three unique
dhps mutant genotypes (Ala-Arg-Pro, Thr-Arg-Ser, and Ala-Arg-
Ser) and 5 MS9 alleles, (TA)8 to (TA)12. Of the 15 possible com-
binations of dhps and MS9 alleles, we identified 7 with an excess of
Ala-Arg-Ser/(TA)10.
Intercontinental population structure. In order to minimize
bias in analyses of population structure, we tested for linkage be-
tween microsatellite loci (62). Because the Pneumocystis jirovecii
draft genome is in 356 contigs (32, 63) rather than in chromo-
somes, we could not rely on genetic maps and instead tested link-
age disequilibrium between markers. Bonferroni-corrected per-
population pairwise tests of linkage disequilibrium showed no
significant linkage disequilibrium between any locus pairs in any
of the three populations (results not shown).
Using the 8 unlinked microsatellites, we examined the extent of
genetic differentiation between P. jirovecii populations from
Uganda, San Francisco, and Spain. We employed UniFrac, a
widely used method for probing the genetic diversity between mi-
crobial communities, which can draw conclusions about the rel-
ative distances between multiple populations. In this analysis, P.
jirovecii isolates from Uganda were genetically distinct from those
in San Francisco and Spain (Fig. 2A). Principal coordinates anal-
ysis revealed that the first coordinate explained approximately
one-half (53.8%) of the observed genetic difference between
Uganda isolates and the other populations (Fig. 2B). Finally, we
constructed a median-joining network analysis charting potential
mutational intermediates between observed P. jirovecii isolates.
This showed little structure between populations, with the excep-
tion being that Uganda occupied a restricted range of genetic di-
versity (Fig. 2C).
We also evaluated genetic distances between these populations
FIG 1 Per-population diversity index for each microsatellite studied. Nine
microsatellites were typed in multiple samples from Uganda (triangles), San
Francisco (circles), and Spain (squares), and heterozygosity (He) values were
calculated for each population. Mean He values are indicated by horizontal
bars. A higher He value indicates that a marker is more variable and thus more
informative for population and transmission studies. Marker MS9 (shaded)
was determined to be in linkage disequilibrium with the dhps locus.
FIG 2 Limited population structure and genetic differentiation between disease-causing P. jirovecii populations. (A) UniFrac revealed a distinct genetic division
between Uganda and San Francisco/Spain but little genetic difference between P. jirovecii isolates from San Francisco and Spain. (B) Principal coordinates
analysis demonstrated that approximately one-half of the genetic difference between population clusters was associated with geographic differences. (C) A
median-joining network predicts potential mutational paths between haplotypes. The samples from Uganda (black circles) show clustering on one side of the
network, likely leading to the differences seen in the other analyses.
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using RST (52) and FST (53), two classic measures of population
demographic history (64). Similar to our previous analyses, RST
and FST suggested that while Ugandan samples were significantly
divergent from the San Francisco and Spain populations, there
was limited genetic differentiation between the three populations
overall (Table 3) (65). Specifically, RST, which assumes a stepwise
mutation model of microsatellite evolution, revealed no genetic
distance between the populations from San Francisco and Spain
and limited distances in the Uganda-San Francisco and Uganda-
Spain comparisons (RST range, 0.017 to 0.125). FST also revealed
limited genetic distances between populations (FST range, 0.022 to
0.067).
Relatedness between isolates within individuals and within a
single population. To maximize the efficiency of a potential mi-
crosatellite genotyping scheme, we determined the minimum
number of microsatellite loci necessary for discriminating be-
tween strains, using both the loci with the greatest heterozygosity
and those with the greatest amplification efficiency (see Table S3
in the supplemental material). We achieved high resolution
(Simpson’s D, 0.999) across all specimens tested by using the 6
most heterozygous markers (MS6, MS8, MS7, MS1, MS3, and
MS5) (see Table S3 in the supplemental material). This extensive
diversity is similar to the diversity described in both Pneumocystis
(30) and other pathogens (66–69), making this typing method a
powerful tool for P. jirovecii population genetic studies (56).
In order to evaluate the suitability of this array to study the
transmission of P. jirovecii in humans, we investigated paired
specimens collected from the same patient. This analysis was re-
stricted to isolates from San Francisco, which included five isolate
pairs (10 isolates) in which two samples were taken from the same
individual. The genotypes of each pair are shown in Table S4 in the
supplemental material. In a neighbor-joining phylogeny of all San
Francisco samples, all paired isolates grouped closely together,
with differing extents of genetic similarity (Fig. 3). The extent of
genetic similarity between paired isolates was reflective of the time
elapsed between collection of the two isolates (see Table S4 in the
supplemental material).
To more rigorously investigate this finding, we employed
eBurst, a tool developed to study outbreaks and explore pathogen
transmission dynamics (59, 70). eBurst visualizes relationships
(edges) between individual parasite isolates (nodes) to generate
hypotheses about pathogen relatedness. We investigated all San
Francisco isolates from the years 2008 to 2011 for which there
were complete haplotypic data at the 6 most informative markers
(including three isolate pairs). eBurst analysis showed that the two
isolate pairs that were temporally closest to one another (SF45 and
SF46 in Table S4 in the supplemental material) were identical at
these six markers, while the third isolate pair (SF47) was closely
related, differing at only one locus (Fig. 4). The other paired iso-
lates (SF48 and SF49) contained missing alleles and could not be
included in this analysis (see Table S4 in the supplemental mate-
rial).
DISCUSSION
Understanding the population genetics and transmission dynam-
ics of fungal pathogens is key for understanding their life history
and for designing new prevention and treatment strategies. Ap-
propriate strain typing methods are crucial to achieve this under-
standing (71). Here, we introduce the first multilocus microsatel-
lite genotyping scheme for Pneumocystis jirovecii. In contrast to
past genotyping schemes, which rely in large part on genic coding
regions, including potential drug resistance (DHFR, DHPS, and
SOD) genes and housekeeping (mtLSU-rRNA and mt26S) genes
(25, 27, 31), we employ microsatellites, most of which are non-
coding (see Table S1 in the supplemental material). Thus, this
genotyping method carries a high discriminatory index that may
be relatively free of selective pressure or functional constraints,
making it a useful technique for studying population structure,
sulfonamide resistance, and transmission dynamics. Microsatel-
lites are widely employed for genotyping individuals owing to
their robustness, scalability, and high information content. Given
these advantages, this genotyping approach will enable studies
that improve our understanding of P. jirovecii biology.
Using these microsatellite markers, we observed limited genetic
differentiation between P. jirovecii populations from Uganda, the
United States, and Spain. This observation was supported by an eco-
FIG 3 Neighbor-joining phylogenetic tree of P. jirovecii clinical isolates from
San Francisco. Repeat samples from the same clinical episode produced an
identical genotype (SF45-1 and -2 and SF46-1 and -2). The other paired sam-
ples were genetically similar between samples but not identical. The other
points represent isolates from patients from which a single sample is available.
Very few samples had identical genotypes, suggesting that the six-microsatel-
lite array will have a high discriminatory power between isolates.
TABLE 3 Pairwise RST and FST statistics for between-population
pairwise comparisons
Source
RST or FST (95% CI)
a
Uganda San Francisco Spain
Uganda 0.125 (0.074–0.220) 0.115 (0.060–0.233)
San Francisco 0.048 (0.020–0.090) 0.017 (0.044–0.044)
Spain 0.067 (0.036–0.109) 0.022 (0.006–0.043)
a Data from all 8 neutral microsatellite loci were used to calculate RST (above the
diagonal) and FST (below the diagonal) in SPAGeDi v1.4. In general, an FST or RST
value of 0 to 0.05 indicates little genetic differentiation, 0.05 to 0.15 indicates moderate
differentiation, 0.15 to 0.25 indicates substantial differentiation, and 0.25 to 1.00
indicates very great genetic differentiation. CI, confidence interval.
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logical clustering algorithm (Fig. 2A) and classical measures of ge-
netic distance (Table 3), both of which indicate a slight divergence of
the Ugandan isolates but relatively little divergence overall. Principal
coordinates analysis revealed that approximately one-half of the ge-
netic differences between all three populations could be explained by
geography (Fig. 2B), with the maximum distance occurring in coor-
dinate one, which separated Uganda from San Francisco and Spain.
Furthermore, a median-joining network showed that isolates from all
three sites were thoroughly admixed, with the only notable trend
being that Ugandan isolates clustered loosely in one part of the net-
work (Fig. 2C).
The relative lack of genetic divergence that we observed be-
tween sites, and over time, is similar to what has been reported
before (72–74). This has several potential explanations, including
the following: (i) P. jirovecii underwent a recent global spread, (ii)
P. jirovecii has a low mutation rate, or (iii) intercontinental gene
flow between P. jirovecii populations occurs frequently. Our un-
derstanding of Pneumocystis populations will be further enhanced
as the P. jirovecii genome takes a more complete form and as
additional samples from other regions are analyzed.
Interestingly, we identified one microsatellite linked to the
dhps gene, which encodes the enzymatic target of sulfonamide
antibiotics that are used to treat and prevent PcP. Polymorphisms
in dhps are associated with exposure to antifolate drugs (10, 75)
and, in some studies, clinical outcomes (76–79). All 13 isolates
from Uganda harbored mutations in dhps: three with both the
Thr55Ala and Pro57Ser substitutions and 10 with the single
Pro57Ser substitution. These mutant haplotypes of dhps likely re-
flect directional selection by sulfonamide antimicrobials used to
treat infections; consistent with this hypothesis, we observed very
low heterogeneity in the microsatellite locus linked to dhps in
Ugandan isolates (He  0.282). In contrast, the isolates from
Spain, which were largely sulfa naive and which harbored primar-
ily wild-type dhps haplotypes, demonstrated a higher heterozygos-
ity at this dhps-linked locus (He  0.632). Taken together with
evidence that antibiotic pressure causes changes in dhps mutant
genotype frequency (73), this pattern is consistent with a selective
sweep occurring around the dhps locus due to drug pressure, as
has been observed in pathogens such as Plasmodium falciparum
(36). In order to confirm this, further studies will require addi-
tional markers near the dhps locus and greater numbers of isolates
bearing wild-type and mutant dhps haplotypes.
In addition to understanding population structure and drug
selection, microsatellite analysis has potential as a tool for molec-
ular epidemiology studies evaluating transmission. The currently
used multilocus genotyping schemes have revealed that (i) specific
P. jirovecii strains are associated with failure of prophylaxis (80)
and can cause more-virulent PcP episodes (81), (ii) specific strains
persist in hospitals for weeks at a time (80), and (iii) P. jirovecii
strains can be acquired later in life by immunocompromised and
immunocompetent patients (22, 82). Despite this wealth of
knowledge, the current multilocus genotyping strategies have left
many questions regarding transmission of P. jirovecii unanswered.
For example, while it is clear that infants and immunocompetent
adults are environmental reservoirs for P. jirovecii (83–87), there is
not yet molecular evidence that these reservoirs are an important
source of disease-causing P. jirovecii transmission to immuno-
compromised individuals. Because there is compelling evidence
that transiently colonized immunocompetent mice can transmit
P. jirovecii to immunosuppressed mice and vice versa (88, 89),
studies of P. jirovecii transmission among immunocompetent and
immunosuppressed humans may help uncover a mechanism for
disease prevention. A highly discriminating genotyping method
with a stepwise mutation model would prove useful in addressing
this and other questions.
The microsatellite genotyping method described here could help
FIG 4 Related P. jirovecii genotypes in the San Francisco population. eBURST outbreak analysis on San Francisco samples in which a complete six-microsatellite
haplotype was available. Paired samples are highlighted in gray. Two pairs (SF45-1 and -2 and SF46-1 and -2) were identical to one another and occurred in the
same clinical episode of PcP. Another pair of isolates (SF47-1 and -2) were related, with only one microsatellite difference.
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reveal details of P. jirovecii reservoirs and transmission. By assessing
five paired clinical samples (10 isolates), we showed that this ap-
proach has high discriminatory power, making it ideal for molecular
epidemiological studies (56). Among our five paired isolates, we ob-
served two cases (SF45 and SF46) in which the two samples in the pair
had identical genotypes in a clinical scenario consistent with a single
infection. In the case of SF45, both samples were collected by a single
bronchoscopy in two different lobes of the lung. In the case of SF46,
the first sample was collected by bronchoscopy upon initial presen-
tation, and the second sample was collected 15 days later after clinical
deterioration despite antifolate therapy. The last three cases (SF47,
SF48, and SF49) all represent PcP patients who received PcP therapy
but experienced a recurrence weeks to months later. In all three cases,
the pairs were genetically close, but not identical, similar to past ob-
servations (61). This finding could be explained in multiple ways,
including the following: (i) these patients may have been infected
with multiple P. jirovecii strains, which were differentially detected at
different time points (90), or (ii) after clinical resolution of their ini-
tial PcP case, these patients returned home and were subsequently
colonized by genetically related—though not identical—organisms.
Importantly, these data show that this method provides high discrim-
inatory power between infections: other than those isolate pairs ex-
pected to be related, there were no identical isolates and only two
related isolates (Fig. 3 and 4). This observation suggests that this
genotyping method will prove useful for future studies of P. jirovecii
outbreaks and transmission dynamics. Additionally, work from oth-
ers suggests that PCR-based P. jirovecii genotyping approaches may
prove successful even in immunocompetent individuals (91), en-
abling future studies of transmission between immunocompromised
patients and immunocompetent health care workers or close con-
tacts.
Pneumocystis jirovecii remains an important opportunistic
pathogen and causes significant disease in immunocompromised
individuals. Many questions about the biology of the organism
remain unanswered, and the PcP disease burden is incompletely
understood. Molecular epidemiology studies have the potential to
provide critical information concerning organismal biology, and
insights from these studies could impact health policy and influ-
ence medication use in patients. While high-resolution genotyp-
ing methods, such as this one, should be applied with care to some
study types (61, 73), our approach provides a stepwise mutational
model, high typeability, and high discriminatory power that will
be valuable for future molecular epidemiological studies of P.
jirovecii.
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